Objectif
Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012. The frequency of complications after surgery is relatively high, but rapid and safe monitoring methods are missing.
MD Biomedical AB has addressed this need and developed a radically new and innovative piece of medical equipment that is gently attached on the surface of the bowel for sampling of biomakers. This makes it possible to detect complications within minutes, at an early stage of illness, and long before patient systemic indications.
The possibility of rapid counteractions improves the treatment of the patient and save health care costs.
The feasibility study comprises one work package divided in 6 tasks and shall in measurable terms assess the functional, medical, economic, and environmental effects and the deliverable is a feasibility report including a business plan.
Champ scientifique
Programme(s)
Thème(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
90719 UMEA
Suède
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.